Duloxetine
Product Images NDC 68071-2709

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-2709). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2709 3)

Label for Duloxetine 60mg delayed-release capsules, 30 count, by NuCare Pharmaceuticals, Inc. The label states each capsule contains 67.3mg Duloxetine Hydrochloride USP equivalent to 60mg Duloxetine. Includes labeler information, NDC 68071-2709, and storage instructions to keep at controlled temperature 68-77°F, with a warning to keep out of reach of children.*

FDA Label Image

Camber-logo (Camber Logo)

FDA Label Image

Duloxetinestructure (Duloxetinestructure)

Chemical structure diagram of Duloxetine hydrochloride showing its molecular arrangement including a thiophene ring, an amine group, and a naphthalene moiety.*

FDA Label Image

Figure1 (Figure1)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between two treatments: Placebo and Duloxetine. The x-axis represents time from randomization to relapse in days, while the y-axis shows the proportion of patients who relapsed, ranging from 0 to 1. The graph shows distinct curves for each treatment group.*

FDA Label Image

Figure10 (Figure10)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. The graph features two lines representing placebo and Duloxetine treatment groups.*

FDA Label Image

Figure2 (Figure2)

A survival curve graph comparing the proportion of patients with relapse over time (days) between Duloxetine and placebo treatments. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients experiencing relapse, illustrating a difference in relapse rates between Duloxetine and placebo groups.*

FDA Label Image

Figure3 (Figure3)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The y-axis represents percentage of patients improved, decreasing as the percent improvement in pain increases on the x-axis. Four distinct lines compare the efficacy of Duloxetine doses and placebo over the range of pain improvement.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg administered twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph shows trends of improvement across various pain improvement percentages for these three groups.*

FDA Label Image

Figure5 (Figure5)

A line graph comparing the percentage improvement in pain from baseline over various thresholds for three groups: Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and a placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure6 (Figure6)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120mg, 60mg, 20mg once daily doses, and placebo. Each dose is represented by a different line style, showing treatment effects across various levels of pain improvement.*

FDA Label Image

Figure8 (Figure8)

A line graph comparing placebo and Duloxetine 60/120 mg once daily, showing the percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph illustrates a higher percentage of patient improvement with Duloxetine compared to placebo across various pain improvement percentages.*

FDA Label Image

Figure9 (Figure9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two data series: Placebo and Duloxetine 60 mg once daily, illustrating patient response improvements over varying pain improvement thresholds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.